Rare Earth elements or metals (REEs) are essential elements in clean-energy technologies. In recent years REEs have received plenty of coverage concurrent to growing environmental concerns.  The rare-earth topic is no longer obscure and discussions regarding future REE shortages are beginning to emerge in mainstream media. Today international governments and organizations are pushing efforts to develop solutions to the rising scarcity threat, one of the biggest being that only 1 percent of critical materials are currently being recycled (they are difficult to recover economically), and so the race to find viable sources for REEs is on. Read more: International Lithium Corp. A Potential Source For Green Technology Minerals.

BOSTON - June 26, 2014 (Investorideas.com Newswire) SoundView Technology Group releases the recent research update on NXT-ID Inc. (OTCQB: NXTD) and its smart wallet, Wocket™.

Recent developments following the June 11th update include the Company has filed for a NASDAQ application and appointed a new independent Board member to satisfy that requirement for listing.

Wocket Launches into Waiting Market

Kris Tuttle & Stephen Waite – June 11, 2014 Summary: The Wocket™ was officially launched on May 28th at the Plaza Hotel in NYC. All the feedback we received from attending suggests that consumers who get a chance to see and understand it, immediately want one. It's a viable way to deliver something consumers can use as a digital wallet that is secure, private, and able to handle all their payment, identification, and loyalty needs. The Wocket is really a wallet replacement, and the functional demonstration worked very well. We'll be monitoring the progress and consumer reaction very closely over the next few months with an eye to validating our IV model, which currently suggests a stock value of $11.70/share. We have also extended our forecast to arrive at a projected IV in 2015 of $20.55.

Read more: Breaking Tech News: Analyst Update; NXT-ID Inc. (OTCQB: NXTD) Wocket Launches into Waiting Market

SAN DIEGO - June 25, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19th, is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at http://aethlonmedical.investorroom.com/index.php?s=19. Once the page has been launched, click on the "listen to the webcast" icon.

The presentation covered the following topics:

• A status report on the first FDA approved study of Hemopurifier therapy in the United States, including Aethlon's clinical progression strategy to advance infectious disease and oncology treatment indications.
• A review of clinical safety data and efficacy observations resulting from Hemopurifier administration to HIV and Hepatitis c (HCV) infected individuals.

Read more: Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Online Access to...

SAN ANTONIO - June 24, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation. Chairman and CEO, Craig Dionne, PhD, presented the company overview and clinical trial updates for G-202 at the 2014 BIO International Convention, today, Tuesday, June 24th, at 11:15 PDT, in San Diego, CA.

Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study in hepatocellular (HCC) patients who had previously progressed on, or who were intolerant of, sorafenib. Historically, this patient population has a median time to progression of only two months when they enter subsequent clinical trials. Impressively, 80% of patients treated with G-202 had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at 4 months on study.

Read more: Breaking Biotech News: GenSpera (OTCQB:GNSZ) Releases 2014 BIO International Presentation and HCC...